Title
Clinicopathological significance of lymphangiogenesis detected by immunohistochemistry using D2-40 monoclonal antibody in breast cancer

Author(s)
Abe, Noriko; Ohtake, Tohru; Saito, Katsuharu; Kumamoto, Kensuke; Sugino, Takashi; Takenoshita, Seiichi

Citation
Fukushima Journal of Medical Science. 62(1): 57-63

Issue Date
2016

URL
http://ir.fmu.ac.jp/dspace/handle/123456789/521

Rights
© 2016 The Fukushima Society of Medical Science

DOI
10.5387/fms.2015-10

Text Version
publisher
Lymphangiogenesis in breast cancer

Fukushima J. Med. Sci., Vol. 62, No. 1, 2016

[Original Article]

Clinicopathological significance of lymphangiogenesis detected by immunohistochemistry using D2–40 monoclonal antibody in breast cancer

Noriko Abe1), Tohru Ohtake1), Katsuharu Saito1), Kensuke Kumamoto1), Takashi Sugino2) and Seiichi Takenoshita1)

1)Department of Organ Regulatory Surgery, Fukushima Medical University, 2)Division of Diagnostic Pathology, Shizuoka Cancer Center Hospital

(Received March 25, 2015, accepted April 6, 2016)

Abstract
To elucidate the association between the lymphangiogenesis and clinicopathological factors including the survival in breast cancer, 91 Japanese patients with breast cancer were investigated. The lymphangiogenesis was evaluated by the count of lymph vessel density (LVD) with immunohistochemical method using D2–40 monoclonal antibody, a specific marker for lymphatic endothelial cells. D2–40-positive lymph vessels were detected in 87 of 91 cases, and were mainly distributed in the peritumoral lesions or around the tumor edge. There was a significant difference in disease-free survival (DFS) and overall survival (OS) between patients with high LVD and with low LVD (p = 0.02, 0.01, respectively, log-rank test). In addition, LVD significantly correlated with the following clinicopathological factors: menopausal status (p < 0.01), tumor size (p < 0.01), lymph-node status (p = 0.01) lymphatic vessel invasion (LVI) (p < 0.01), blood vessel invasion (BVI) (p = 0.03) and estrogen receptor status (ER) (p = 0.02).

Those data suggest that D2–40 monoclonal antibody is a useful marker for evaluating the LVD and its evaluation is helpful to predict the survival in breast cancer.

Key words: Breast cancer, Lymphangiogenesis, LVD, D2–40, Immunohistochemistry

Introduction
Breast cancer is the most common type of cancer in Japanese women, with an estimated 40,000 new cases and the second leading cause of cancer-related deaths in Japanese women, with an estimated 13,000 deaths in 2013. Although chemotherapy is relatively effective for breast cancer after surgical treatment so that it contributes to the survival, some parts of patients still died of the metastasis to distant organs due to the acquisition of chemo resistance. Furthermore, axillary lymph node metastasis is one of the most important prognostic factors for breast cancer.

In general, cancer metastasis occurs by invasion to blood or lymphatic vessels. It is well known that newly formed blood vessels support haematogenous spread and facilitate tumor growth2), but little is known about the mechanism of lymph node metastasis involved in the lymphatic spread.

Recent studies on the biological role of lymphangiogenic factors, such as vascular endothelial growth factor-C (VEGF-C) and -D (VEGF-D), contribute to elucidate the association between lymph node metastasis and lymphangiogenesis. VEGF-C expression is found in various human tumors, such as breast3,4), colon5,6), lung4,7,8), thyroid9-11), gastric12), and squamous cell cancers4), mesotheliomas13), neuroblastomas14), sarcomas15) and melanomas16). Furthermore, and expression of VEGF-C mRNA has re-
cently been shown to correlate with the rate of metastasis to lymph nodes in breast\textsuperscript{3)}, colorectal\textsuperscript{6)}, gastric\textsuperscript{12)}, thyroid\textsuperscript{9,10)}, lung\textsuperscript{8)} and prostate\textsuperscript{15)} cancers.

The lymphangiogenesis is usually evaluated by the count of lymph vessel density (LVD) using specific markers for lymphatic endothelial cell, such as vascular endothelial growth factor receptor-3 (VEGFR-3), podoplanin, LYVE-1 are available to detect lymphatic vessels\textsuperscript{16}). In breast cancer, LVD detected by specific markers for lymphatic endothelial cells such as VEGFR-3, podoplanin and LYVE-1 is reported to be associated with the survival\textsuperscript{17-19}). However, there have not been reports on the evaluation of LVD in breast cancer with immunohistochemical method using a more specific and sensitive marker for lymphatic endothelial cells, D2-40 monoclonal antibody. D2-40 is a kind of monoclonal antibody for podoplanin.

Here we have evaluated the LVD in breast cancer using the D2-40 monoclonal antibody and reported the association between LVD and clinicopathological factor including the survival.

### Materials and Methods

#### Patients and Tumor Samples

We examined 91 female patients of invasive ductal cancer treated at the Second Department of Surgery of Fukushima Medical University, Japan, between January 1991 through December 1996. All patients underwent modified radical mastectomy or breast partial mastectomy with axillary lymph node dissection. Each patients was treated with suitable adjuvant therapy (chemotherapy or endocrine therapy or none) postoperatively. All protocols were reviewed and approved by the ethics committee of Fukushima Medical University (No. 1202). The patients were staged according to Japanese Breast Cancer Society criteria, which were based on the UICC-TNM classification. We excluded patients who had received prior chemotherapy with distant metastasis at the time of diagnosis. The mean age at time of surgery was 54 year-old (range 30-81 years). Follow-up for the patients included in the survival analysis was updated in June 2006 (median follow-up was 120 months [range 8-179 months]). At that time, 8 patients had local, 27 patients had distant metastasis, and 25 patient had died of breast carcinoma, 66 patients were alive. All tumors were classified with histopathologically as invasive ductal carcinoma of no special type, according to the World Health Organization criteria\textsuperscript{20}).

### Immunohistochemical Staining

Immunohistochemical staining was performed using an ENVISION method (Dako Cytomation). Serial 5-µm thick paraffin-embedded sections were used in this study, and the sections were deparaffinized with xylene and dehydrated with ethanol. No antigen retrieval was required. Endogenous peroxidase was blocked by immersing the slides in 0.3% hydrogen peroxide in absolute methanol for 20 minutes at room temperature. After washing three times in PBS, non-specific staining was blocked by incubation with 5% skimmed milk in PBS and the sections were incubated at 4°C overnight with D2-40 monoclonal antibody (Dako Cytomation, Carpinteria, California; dilution 1:100). After washing three times in PBS for 5 minutes, the sections were incubated with ENVISION+, Mouse/HRP (Dako Cytomation, Carpinteria, California) for 30 minutes at room temperature. The sections were then washed three times in PBS for 15 minutes, and the immune complex was visualized by incubating the sections with 0.2 mg/mL diaminobenzidine and 0.05% (vol/vol) H₂O₂ in PBS for 5 minutes. The sections were counterstained with hematoxylin and mounted.

#### Evaluation of Immunohistochemistry

Determination of LVD was performed according to Weidner et al.\textsuperscript{21}). The immunostained sections were scanned by light-microscopy using a low magnification (40x) and the areas of tissue with the greatest number of distinctly highlighted microvessels (“hot spot”) were selected. Microvessel density was then determined by counting all immunostained vessels at a total magnification of 200x corresponding to an examination area of 0.9499 mm². Five hot spots were chosen in each section. Mean values of the microvessels in the five fields were entered into the statistical analysis. Any immunoreactive cells were considered as an endothelial cell and a countable microvessel, even in the absence of a lumen. Two investigators without their knowledge of the clinicopathological findings assessed microvessel counts.

Lymph vessel invasion (LVI) and blood vessel invasion (BVI) was considered evident if at least one tumor cell cluster was clearly visible inside the vascular space. Histological grade was assessed according to Elston-Ellis modification of Scarff-Bloom-Richardson grading system\textsuperscript{22}).
Correlation between LVD and clinicopathologic characteristics was evaluated by unpaired Student’s t test. Survival rates were analyzed using Kaplan-Meier method and the log-rank test. Overall survival (OS) was defined as the period from primary surgery until death of the patient. Death from a cause other than breast cancer, or survival until the end of the observation period, was considered censoring event. Disease-free survival (DFS) was defined from the end of primary therapy until first evidence of progression of disease. All these analysis were performed by the statistical package, STAT-
Result

D2-40 expression in breast cancer tissue

D2-40 positive lymph vessels were detected in 87 of 91 cases. All of the D2-40-positive lymphatic vessels were observed in peritumoral lesions or around the tumor edge (Fig. 1). In normal breast tissue, lymph vessels were seen in interductal stroma or around the blood vessels. Intratumoral lymphatic vessels were lower in number when compared with peritumoral area.

Correlation of LVD with clinocopathological factors

The mean LVD was 7.24±5.68 microvessels/mm² (range 0-25.48). Association between LVD and clinopathological findings was statistically analyzed (Table 1).

Table 1. The relationship between LVD and clinicopathological variables in 91 breast cancer cases.

| Characteristics                      | No. | Mean LVD     | P-value (t-test) |
|-------------------------------------|-----|--------------|-----------------|
| menopausal status                   |     |              |                 |
| post                                | 48  | 5.78±4.34    | <0.01           |
| pre                                 | 43  | 8.87±6.55    |                 |
| Tumor size                          |     |              |                 |
| < 5 cm                              | 85  | 6.80±5.35    | <0.01           |
| ≥ 5 cm                              | 6   | 13.41±7.14   |                 |
| Lymph node status                   |     |              |                 |
| negative                            | 38  | 5.56±4.48    | 0.01            |
| positive                            | 53  | 8.44±6.16    |                 |
| Histological grade                  |     |              |                 |
| HG1, HG2                            | 78  | 7.60±5.83    | 0.14            |
| HG3                                 | 13  | 5.05±4.18    |                 |
| Lymph vessel invasion               |     |              |                 |
| negative                            | 53  | 4.42±3.97    | <0.01           |
| positive                            | 38  | 11.16±5.40   |                 |
| Blood vessel invasion               |     |              |                 |
| negative                            | 81  | 6.78±5.23    | 0.03            |
| positive                            | 10  | 10.93±7.87   |                 |
| ER                                  |     |              |                 |
| negative                            | 23  | 9.52±6.11    | 0.02            |
| positive                            | 68  | 6.47±5.35    |                 |
| PgR                                 |     |              |                 |
| negative                            | 23  | 8.66±5.97    | 0.11            |
| positive                            | 68  | 6.61±5.46    |                 |
| HER2                                |     |              |                 |
| negative                            | 72  | 6.82±5.82    | 0.17            |
| positive                            | 19  | 8.82±4.93    |                 |

LVD was significantly correlated with menopausal status ($p<0.01$), tumor size ($p<0.01$), lymph-node status ($p=0.01$), LVI ($p<0.01$), BVI ($p=0.03$) and estrogen receptor status (ER) ($p=0.02$). No association was found between LVD and histological grade, progesterone receptor status (PgR) and HER2 status.

Prognostic Relevance of LVD

To analyze the correlation between LVD and patient’s prognosis, the patients were divided into two groups; lower LVD and higher LVD. The cut-off point was mean LVD. Kaplan-Meier product limit estimates of disease-free survival (DFS) and overall survival (OS) were plotted in Fig. 2. Patients with higher LVD had a poorer survival than those with lower LVD in both DFS and OS ($p=0.02$, 0.01, respectively, log-rank test).
Lymphangiogenesis in breast cancer

Discussion

Lymphangiogenesis is considered to be essential to lymph node metastasis in human cancer and is usually evaluated by the count of LVD using specific markers for lymphatic endothelial cells. Axillary lymph node metastasis is known to be one of the most important prognostic factors in breast cancer, and LVD evaluated by using specific markers for lymphatic endothelial cells such as VEGFR-3, podoplanin and LYVE-1 has been reported to be associated with the survival in breast cancer\textsuperscript{17-19}. However, there have not been reports on the evaluation of LVD in breast cancer using a D2-40 monoclonal antibody, more specific and sensitive marker for lymphatic endothelial cells\textsuperscript{20}. D2-40 is a fixation-resistant epitope on a 40 kDa O-linked sialoglycoprotein, which may be identical to podoplanin\textsuperscript{21}, expressed in lymphatic endothelium but not in blood vessels\textsuperscript{22,23}. Therefore, we used D2-40 to investigate the evaluation of LVD in breast cancer.

In the present study, D2-40-positive lymphatic vessels were detected in almost all the breast cancer cases (87 of 91 cases), and were predominantly observed in the peritumoral lesions or around the tumor edge, but a little in the intratumoral lesions. The results indicate that D2-40 monoclonal antibody is a useful marker for detection of lymph vessels. The distribution pattern of lymph vessels seems to be common in many cancers, especially in breast cancer\textsuperscript{(18, 19, 27)}. Padera 	extit{et al} reported that the absence of intratumoral lymph vessels may result from compressing and/or destructing lymphatics by proliferating tumor cells\textsuperscript{(28)}. However, the reason for a little intratumoral lymphatic vessels has been debated until now\textsuperscript{(28-32)} and still remains unclear.

There have been several different reports about the correlation between the LVD and clinicopathological factors or patients’ survival in breast cancer\textsuperscript{(17-19, 27, 29, 33-36)}. Some reports showed positive correlation between LVD and tumor aggressiveness or poor prognosis\textsuperscript{(17-19, 35)}, and the other displayed no correlation between them\textsuperscript{(27, 29, 33, 34, 36)}. Although the reason of the discrepancy is not enough discussed, it may be due to the difference in specificity and sensitivity of specific markers used for lymph vessels, selection of “hot spot” areas and cut-off point.

In the present study, our data indicated the significant association between LVD and lymph node metastasis and LVI. LVD is also correlates with other prognostic factor, menopausal status and ER status. Pre-menopausal and ER-negative breast cancer patients is usually have a poorer prognosis than those of Post-menopausal and ER-positive patients. Furthermore, patients with high LVD showed poor prognosis by comparison to those with low LVD. The process of lymphatic metastasis is thought to involve proliferation of lymphatic vessels (lymphangiogenesis), lymphatic invasion and lymph node metastasis. Our findings that high LVD was associated with lymph node metastasis, LVI and poor prognosis suggest an important role of lymphangiogenesis in the progression of breast cancer.

In conclusion, D2-40 monoclonal antibody may be a useful marker to evaluate the lymphangiogenesis, and its evaluation is helpful to predict the prog-

---

**Fig. 2.** The analysis of disease-free survival (DFS) and overall survival (OS) in breast cancer according to LVD.
nosis or survival.

References

1. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of America\nPathologists Consensus Statement 1999. Arch Pathol Lab Med, 124: 966-978, 2000.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature, 438: 932-936, 2005.
3. Kurebayashi J, Otsuki T, Kunisue H, et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res, 90: 977-981, 1999.
4. Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol, 153: 103-108, 1998.
5. Andre T, Kotelevets L, Vaillant JC, et al. VEGf, VEGf-B, VEGf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer, 86: 174-181, 2000.
6. Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer, 83: 887-891, 2000.
7. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res, 6: 2431-2439, 2000.
8. Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe Y. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg, 119: 804-813, 2000.
9. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol, 155: 1967-1976, 1999.
10. Fellmer PT, Sato K, Tanaka R, et al. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery, 126: 1056-1061; discussion 1061-1062, 1999.
11. Shushanov S, Bronstein M, Adelaide J, et al. VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer, 86: 47-52, 2000.
12. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res, 5: 1823-1829, 1999.
13. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer, 81: 54-61, 1999.
14. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastosomas. Clin Cancer Res, 6: 1900-1908, 2000.
15. Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer, 80: 309-313, 1999.
16. Altitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature, 438: 946-953, 2005.
17. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res, 9: 5313-5317, 2003.
18. Bono P, Wasenius VM, Heikkila P, Lundin J, Jackson DG, Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res, 10: 7144-7149, 2004.
19. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat, 91: 125-132, 2005.
20. The world Health Organization Classification of Tumors of theBreast. 4th Edition. International Agency for Research on Center Lyon, 2012.
21. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med, 324: 1-8, 1991.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
23. Van der Auweria I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res, 11: 7637-7642, 2005.
24. Sonne SB, Herlihy AS, Hoei-Hansen CE, et al. Identity of M2A (D2-40) antigen and gp36 (Aggrus, TIA-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch, 449: 200-206, 2006.
25. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of
angiosarcomas. Mod Pathol, 15: 434-440, 2002.

26. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest, 82: 1255-1257, 2002.

27. Kato T, Prevo R, Steers G, et al. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer, 93: 1168-1174, 2005.

28. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 296: 1883-1886, 2002.

29. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol, 200: 195-206, 2003.

30. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol, 57: 746-751, 2004.

31. Agarwal B, Saxena R, Morimiya A, Mehrotra S, Badve S. Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol, 29: 1449-1455, 2005.

32. van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-Franse LV, Griffioen AW. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett, 254: 128-136, 2007.

33. Jacquemier J, Mathoulin-Portier MP, Valtola R, et al. Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3. Int J Cancer, 89: 69-73, 2000.

34. Nathanson SD, Zarbo RJ, Wachna DL, Spence CA, Andrezewski TA, Abrams J. Microvessels that predict axillary lymph node metastases in patients with breast cancer. Arch Surg, 135: 586-593; discussion 593-594, 2000.

35. Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res, 21: 2351-2355, 2001.

36. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg, 240: 306-312, 2004.